World Heart Day: Celebrating Breakthroughs in Hypertension Treatment and Innovating for Every Heartbeat

On September 29^th, the world comes together to observe World Heart Day, a day dedicated to raising awareness about cardiovascular disease (CVD), the leading cause of death globally. Responsible for approximately 20.5 million deaths each year, CVD remains a critical health challenge, with hypertension—often referred to as the "silent killer"—playing a central role.

Hypertension affects more than 1.28 billion people worldwide, significantly increasing the risk of heart attacks, strokes, kidney disease, and other life-threatening conditions. Every minute, it claims 19 lives and contributes to approximately 10 million deaths annually. In response to this global challenge, our industry has made extraordinary strides in developing innovative therapies that have transformed the landscape of hypertension treatment.

The journey of hypertension treatment began in the mid-20th century with the introduction of diuretics and beta-blockers, the first major breakthroughs in controlling high blood pressure. Diuretics, introduced in the 1950s, work by helping the kidneys remove excess sodium and water from the body, which reduces blood volume and lowers blood pressure. Beta-blockers became widely used in the 1960s, reduce heart rate and the force of contraction, easing the heart's workload and lowering blood pressure.

The next significant advancement in hypertension treatment came with the introduction of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs). These drugs help relax the veins and arteries in the body, lowering blood pressure.

This year, a major breakthrough occurred with the approval of Tryvio, the first antihypertensive drug with a completely new mechanism in 30 years. By blocking endothelin receptors, Tryvio effectively reduces blood pressure in patients who have not responded to other treatments. This innovative approach opens new doors for the management of hypertension, particularly in patients with resistant hypertension, and marks a significant step forward in the fight against this pervasive disease.

Looking ahead, the future of hypertension treatment is promising, with many innovative therapies under development and more than 10 innovative therapies currently in Phase III clinical trials. These advancements hold the promise of more effective and personalized treatments, bringing us closer to a world where hypertension can be fully controlled or even cured.

As we reflect on our industry's continuous progress in combating hypertension, we honor the relentless efforts of scientists, researchers, and industry colleagues who have devoted their lives to this critical cause. Their dedication embodies our shared vision that “every drug can be made and every disease can be treated.” The collaborative spirit that unites us drives the innovation necessary to ensure patients worldwide benefit from these groundbreaking therapies. Together, we can aspire to a future where hypertension is no longer a silent killer but a manageable condition, giving millions the chance to live healthier, longer lives. 

References:

1. Hypertension Fact sheet. Retrieved August 29, 2024, from https://www.who.int/news-room/fact-sheets/detail/hypertension

2. Estimated Hypertension Prevalence, Treatment, and Control Among U.S. Adults. Retrieved August 29, 2024, from https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html

3. Hypertension. Retrieved August 29, 2024, from https://world-heart-federation.org/what-we-do/hypertension/